While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, ...

Innovation is accelerating through bispecifics and dual payload strategies | Emerging ADC development approaches such as ...

Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in ...

Marianne D'Amico-Ferrari has spent 29 years teaching in Trumbull. Families know her as steady and kind. Students describe her ...

Teaching fitness classes in between chemo, a coach's fight with stage 4 cancer ...

Chemotherapy-induced neurotoxicity spans cognitive dysfunction (“chemo brain”), seizures, neuropathies, and encephalopathy. Mechanisms involve disruption of neural networks, altered hippocampal ...

CALABASAS, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering ...

(Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2) — Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged ...

Hair is an important part of our personal identity, so its loss during cancer treatment can be distressing at an already difficult time. However, this can be a positive sign that chemotherapy is ...

Single-agent CD19 CAR-NK cell therapy achieved a complete response in third-line Waldenstrom macroglobulinemia (WM), a type of non-Hodgkin lymphoma Second patient maintains an ongoing complete ...